SCHEMBL5947282

SCHEMBL5947282

c1ccc(Oc2cccc(CNCCc3c[nH]c4ccccc34)c2)nc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 7/20 0.69
▸ MC5R P33032 2/20 0.58
▸ MC3R P41968 2/20 0.58
▸ MC1R Q01726 2/20 0.58
▸ LMNA P02545 2/20 0.51
▸ MEN1 O00255 2/20 0.51
▸ TP53 P04637 1/20 0.51
▸ HTR2A P28223 2/20 0.50
▸ HTR1A P08908 1/20 0.49
▸ DRD2 P14416 1/20 0.49
▸ HTR2C P28335 1/20 0.49
▸ HTR7 P34969 1/20 0.49
▸ HTR6 P50406 1/20 0.49
▸ MAPT P10636 4/20 0.48
▸ MAPK1 P28482 2/20 0.48
▸ ABCG2 Q9UNQ0 1/20 0.48
▸ MITF O75030 1/20 0.48
▸ MAP2K7 O14733 1/20 0.48
▸ NPSR1 Q6W5P4 2/20 0.48
▸ TDP1 Q9NUW8 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5947263 0.89 KMT2A (0.55) KMT2AMC5RMC3RMC1RLMNA
SCHEMBL5947445 0.89 HTR2A (0.68) KMT2AMEN1HTR2AHTR1AHTR7
SCHEMBL5947492 0.86 HTR1A (0.56) KMT2ATP53HTR2AHTR1AMAPT
SCHEMBL5947571 0.86 KMT2A (0.79) KMT2AMC5RMC3RMC1RLMNA
SCHEMBL5947375 0.85 KMT2A (0.71) KMT2AMC5RMC3RMC1RLMNA
SCHEMBL5947427 0.84 KMT2A (0.70) KMT2AMC5RMC3RMC1RLMNA
SCHEMBL5947237 0.83 KMT2A (0.65) KMT2AMC5RMC3RMC1RLMNA
SCHEMBL5947472 0.82 KMT2A (0.70) KMT2AMC5RMC3RMC1RLMNA
SCHEMBL5947705 0.82 KMT2A (0.72) KMT2AMC5RMC3RMC1RLMNA
SCHEMBL5947148 0.82 MC5R (0.75) KMT2AMC5RMC3RMC1RLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060009511-A9 N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor CHEN ZHAOGEN 2006-01-12 — — US claimed
EP-1379239-A2 N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR ELI LILLY AND COMPANY (US) 2004-01-14 — — EP claimed
WO-2002078693-A2 N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR ELI LILLY AND COMPANY (US) 2002-10-10 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060009511-A9 N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor HTR6, HTR2C, HTR1B KMT2A 1269/4885MC5R 50/4885MC3R 86/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback